DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more

Arranon (Nelarabine) - Death - Suspected Cause - Side Effect Reports

 
 



Index of reports > Death (6)

Below is the selection of side effect reports (a.k.a. adverse event reports) related to Arranon (Nelarabine) death. The selected reports were submitted to the FDA during the sample period of about a year.

Possible Arranon side effects in female

Reported by a physician from Japan on 2012-07-25

Patient: female, weighing 39.6 kg (87.1 pounds)

Reactions: Hepatic Function Abnormal, Hyperphosphataemia, Hyperkalaemia, Hypotension, Ventricular Arrhythmia, Acidosis, Coagulation Time Abnormal

Adverse event resulted in: death, life threatening event

Drug(s) suspected as cause:
Arranon
    Dosage: 650mgm2 per day
    Indication: T-Cell Type Acute Leukaemia
    Start date: 2011-04-23
    End date: 2011-04-27

Dexamethasone
    Dosage: 6.6mg per day
    Start date: 2011-04-28
    End date: 2011-04-29

Dexamethasone
    Dosage: 6.6mg per day
    Indication: Neoplasm Malignant
    Start date: 2011-04-20
    End date: 2011-04-20

Dexamethasone
    Dosage: 6.6mg per day
    Start date: 2011-05-06
    End date: 2011-05-06

Dexamethasone
    Dosage: 13.2mg per day
    Start date: 2011-04-21
    End date: 2011-04-27

Other drugs received by patient: Decadron; Hydrocortisone Sodium Succinate; Sodium Bicarbonate; Pentazocine Lactate; Granisetron; Ifosfamide; Allopurinol; Fentanyl; Bosmin; Mucosta; Solita-T NO 3; Furosemide; Atarax; Potassium Chloride; Ketoprofen; Daunorubicin HCL; Fildesin; Methotrexate; Decadron; Polaramine; Diamox; Loxoprofen; Leunase; Furosemide; Seishoku; Lorcam; Platelets; Ketalar



Possible Arranon side effects in female

Reported by a physician from Japan on 2012-07-10

Patient: female, weighing 39.6 kg (87.1 pounds)

Reactions: Hepatic Function Abnormal, Hyperkalaemia, Hyperphosphataemia, Hypotension, Ventricular Arrhythmia, Acidosis, Coagulation Time Abnormal

Adverse event resulted in: death, life threatening event

Drug(s) suspected as cause:
Arranon
    Dosage: 650mgm2 per day
    Indication: T-Cell Type Acute Leukaemia
    Start date: 2011-04-23
    End date: 2011-04-27

Dexamethasone
    Dosage: 13.2mg per day
    Start date: 2011-04-21
    End date: 2011-04-27

Dexamethasone
    Dosage: 6.6mg per day
    Start date: 2011-04-28
    End date: 2011-04-29

Dexamethasone
    Dosage: 6.6mg per day
    Start date: 2011-05-06
    End date: 2011-05-06

Dexamethasone
    Dosage: 6.6mg per day
    Indication: Neoplasm Malignant
    Start date: 2011-04-20
    End date: 2011-04-20

Other drugs received by patient: Leunase; Decadron; Solita-T; Daunorubicin HCL; Methotrexate; Mucosta; Decadron; Hydrocortisone Sodium Succinate; Furosemide; Fentanyl; Ketoprofen; Fildesin; Sodium Bicarbonate; Potassium Chloride; Pentazocine Lactate; Furosemide; Polaramine; Atarax; Bosmin; Lorcam; Ifosfamide; Allopurinol; Granisetron; Diamox; Seishoku; Platelets; Ketalar; Loxoprofen



Possible Arranon side effects in

Reported by a physician from United States on 2012-05-23

Patient:

Reactions: Death

Adverse event resulted in: death

Drug(s) suspected as cause:
Arranon



Possible Arranon side effects in male

Reported by a physician from Japan on 2012-03-15

Patient: male, weighing 43.0 kg (94.6 pounds)

Reactions: Nervous System Disorder

Adverse event resulted in: death

Drug(s) suspected as cause:
Arranon
    Dosage: 650mgm2 per day
    Indication: Precursor T-Lymphoblastic Lymphoma / Leukaemia
    Start date: 2011-02-28
    End date: 2011-03-04

Arranon
    Dosage: 650mgm2 per day
    Start date: 2011-03-22
    End date: 2011-03-26

Cytarabine
    Indication: Cord Blood Transplant Therapy
    Start date: 2011-02-05
    End date: 2011-02-05

Cytarabine
    Indication: Neoplasm Malignant
    Start date: 2011-02-01
    End date: 2011-02-01

Methotrexate
    Start date: 2011-02-01
    End date: 2011-02-02

Methotrexate
    Indication: Neoplasm Malignant
    Start date: 2011-02-01
    End date: 2011-02-01

Vincristine Sulfate
    Dosage: 2mg per day
    Indication: Neoplasm Malignant
    Start date: 2011-02-01
    End date: 2011-02-07

Vincristine Sulfate
    Dosage: 2mg per day
    Start date: 2011-04-14
    End date: 2011-04-21

Other drugs received by patient: Elspar; Bortezomib; Dexamethasone; Mercaptopurine; Cytarabine; Melphalan Hydrochloride; Funguard; Vfend; Etoposide; Zovirax; Cotrim; Azactam; Vicclox; Fludarabine Phosphate; Fludarabine Phosphate; Elspar; Fludarabine Phosphate; Ambisome; Zosyn; Carbenin; Fragmin; Etoposide; Doxorubicin HCL; Prednisolone; Maxipime; Tacrolimus; Targocid



Possible Arranon side effects in male

Reported by a physician from Japan on 2012-02-17

Patient: male, weighing 43.0 kg (94.6 pounds)

Reactions: Nervous System Disorder

Adverse event resulted in: death

Drug(s) suspected as cause:
Arranon
    Dosage: 650mgm2 per day
    Indication: Precursor T-Lymphoblastic Lymphoma / Leukaemia
    Start date: 2011-02-28
    End date: 2011-03-04

Arranon
    Dosage: 650mgm2 per day
    Start date: 2011-03-22
    End date: 2011-03-26

Bortezomib
    Dosage: 1.9mg per day
    Indication: Neoplasm Malignant
    Start date: 2011-04-14
    End date: 2011-04-24

Other drugs received by patient: Fludarabine Phosphate; Prednisolone; Funguard; Vincristine Sulfate; Melphalan Hydrochloride; Ambisome; Vfend; Carbenin; Fludarabine Phosphate; Dexamethasone; Zosyn; Azactam; Doxorubicin HCL; Elspar; Maxipime; Cytarabine; Mercaptopurine; Methotrexate; Zovirax; Vincristine Sulfate; Cytarabine; Cytarabine; Methotrexate; Fragmin; Elspar; Fludarabine Phosphate; Etoposide; Etoposide; Sulfamethoxazole; Tacrolimus; Targocid; Vicclox



Possible Arranon side effects in male

Reported by a physician from Japan on 2012-01-04

Patient: male

Reactions: Movement Disorder, Monoplegia, Muscle Atrophy, Dyspnoea, Muscular Weakness, Decreased Vibratory Sense, Hypoaesthesia, Fall, Nerve Conduction Studies Abnormal, Sensory Disturbance, Nuclear Magnetic Resonance Imaging Abnormal, Areflexia, Nervous System Disorder, Respiratory Arrest, Gait Disturbance

Adverse event resulted in: death

Drug(s) suspected as cause:
Arranon
    Dosage: 650mgm2 per day
    Start date: 2011-03-22
    End date: 2011-03-22

Arranon
    Dosage: 650mgm2 per day
    Indication: T-Cell Type Acute Leukaemia
    Start date: 2011-02-28
    End date: 2011-02-28

Bortezomib
    Indication: T-Cell Type Acute Leukaemia
    Start date: 2011-01-01
    End date: 2011-01-01

Cyclophosphamide
    Indication: T-Cell Type Acute Leukaemia
    Start date: 2011-01-01
    End date: 2011-01-01

Other drugs received by patient: Etoposide; Fludarabine Phosphate; Etoposide; Fludarabine Phosphate; Cytarabine; Melphalan Hydrochloride

-- advertisement -- The American Red Cross
 
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017